Peptide Bio IndexEvidence first. Hype last.
⌕

Semax Human Studies vs Preclinical Research

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited10 min readUpdated Sep 2, 2026
Jump to a section
  1. Overview — what the reviewed sources cover
  2. Human clinical and imaging studies (what exists in humans)
  3. Preclinical (animal and cellular) research — mechanistic and efficacy signals
  4. Where mechanisms are reported (transcriptomics, targets, immune/vascular signals)
  5. Evidence gaps, heterogeneity, and applicability
  6. Reported study-design details from cited sources
  7. Limitations and research gaps
  8. Documentation checklist
  9. Related research supplies
  10. More Semax research
  11. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive compares available human clinical and imaging studies of the synthetic peptide Semax with preclinical (animal and cellular) research to clarify where human evidence exists and where mechanistic or efficacy claims remain rooted in nonclinical models. Semax has been investigated in animal ischemia, spinal cord injury, and neurodegeneration models with transcriptomic and functional endpoints (rats and mice) and has also been assessed acutely in human resting-state fMRI and in several clinical/open studies in stroke and optic nerve disease (older primary literature) (S8, S3, S5, S6, S7, S2, S9, S10, S11, S12).

Overview — what the reviewed sources cover

The reviewed corpus includes genome-wide transcriptomic and mechanistic studies in rodent ischemia models (tMCAO/pMCAO) and spinal cord injury, behavioral and histological evaluations in mouse models of Alzheimer's disease, and functional-connectivity or clinical comparisons in humans (resting-state fMRI and clinical stroke/optic-nerve cohorts). Several studies emphasize Semax effects on immune- and vascular-related gene expression in ischemic brain tissue, while other preclinical work implicates ubiquitination pathways and specific targets such as USP18 and μ-opioid receptors in spinal-cord injury models (S8, S5, S6, S3, S7, S2, S9, S10, S12). [S8] [S3] [S5] [S6] [S7] [S2] [S9] [S10] [S12]

Human clinical and imaging studies (what exists in humans)

Randomized placebo-controlled resting-state fMRI studies in healthy adults detected rapid central nervous system effects after acute Semax administration, including changes in resting-state functional connectivity and increases in rostral default mode network volume within minutes post-dose (fMRI scans taken 5–20 minutes after administration in some protocols) (S2, S9). [S2] [S9]

Clinical and observational human reports available in the reviewed sources include a controlled study in acute hemispheric ischemic stroke patients reporting faster neurological recovery (30 Semax patients vs 80 standard-therapy controls) with reported effective daily doses of 12–18 mg for 5–10 days, an uncontrolled/controlled clinical comparison in optic nerve disease showing improved visual function when Semax was added to standard therapy, and an observational comparison in 110 post‑stroke patients where two 10‑day courses of 6000 mcg/day were associated with higher plasma BDNF and improved Barthel Index outcomes during rehabilitation (S10, S11, S12). [S10] [S11] [S12]

Preclinical (animal and cellular) research — mechanistic and efficacy signals

Rodent ischemia studies report that Semax and related ACTH-like peptides modulate large numbers of differentially expressed genes in the ischemic cortex and penumbra, with effects strongest on immune-response and vascular-related gene sets and substantial normalization of ischemia-induced transcriptomic disturbances at 3–24 hours post‑ischemia in rats (S8, S5, S6). [S8] [S5] [S6]

Other animal-model reports describe Semax improving functional recovery after spinal cord injury in female mice with evidence implicating regulation of ubiquitination pathways (USP18, FTO) and a proposed interaction with the μ-opioid receptor, and Semax (and derivatives) reducing amyloid inclusions and improving cognition in a transgenic mouse model of Alzheimer's disease (S3, S7). [S3] [S7]

Where mechanisms are reported (transcriptomics, targets, immune/vascular signals)

Genome-wide analyses in rat focal ischemia models found Semax alters expression of genes linked to immune-cell activity, chemokines, immunoglobulins, and vascular development or migration, leading authors to highlight immunomodulatory and vascular effects as candidate mechanisms for neuroprotection; separate RNA-seq and network-pharmacology analyses in an SCI mouse model identified USP18-related deubiquitination pathways and suggested μ-opioid receptor interactions as part of Semax's mechanistic profile (S8, S5, S3). [S8] [S5] [S3]

Evidence gaps, heterogeneity, and applicability

Although multiple preclinical studies report transcriptomic, histological, and behavioral effects, the reviewed sources note a relative scarcity of large, randomized, peer-reviewed clinical trials; clinical reports in the reviewed set include small controlled cohorts and observational comparisons from primary literature rather than large multicenter trials, and mechanistic findings from animals (immune, vascular, ubiquitination pathways) have not been consistently validated in well-powered human trials (S1, S8, S3, S10, S12). [S1] [S8] [S3] [S10] [S12]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S9] randomized, placebo-controlled resting-state fMRI Healthy adult humans (resting-state fMRI) not reported in the reviewed source intranasal single acute administration 5–20 minutes post-dose (measured effect window) 1% Semax solution reported; effect measured acutely on default mode network volume
[S2] functional connectivity (resting-state fMRI) assessment Healthy participants (fMRI study) not reported in the reviewed source injection single administration with repeated scans fMRI scans at pre-dose, 5 min, and 20 min after injection Compared Semax, Selank, and placebo; ROI analyses included amygdala and DLPFC
[S10] controlled clinical study (30 Semax vs 80 standard-therapy controls) Acute ischemic stroke patients (clinical controlled study) 12–18 mg per day (reported in the reviewed excerpt) not reported in the reviewed source daily 5–10 days Reported faster neurological recovery and EEG/evoked-potential improvements in Semax group
[S12] observational comparison during rehabilitation Post-stroke patients (observational comparison, n=110) 6000 mcg per day (reported in the reviewed excerpt) not reported in the reviewed source daily two 10-day courses Associated with increased plasma BDNF and improved Barthel Index outcomes versus non‑Semax subgroups
[S3] preclinical spinal cord injury model with molecular analyses Female C57BL/6 mice with T9–T10 spinal cord injury not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Semax improved functional recovery, inhibited LMP-related pyroptosis, regulated USP18 and affected deubiquitination via FTO; network pharmacology suggested μ-opioid receptor as a target
[S5] rodent tMCAO with RNA-Seq transcriptome analysis Rats with transient middle cerebral artery occlusion (tMCAO) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source assessments at 4.5 h and 24 h after tMCAO Semax and ACTH(6-9)PGP reduced ischemia‑induced transcriptome disturbances and normalised many DEGs related to immune and neurosignaling pathways
[S6] RNA-Seq analysis of regional gene expression in rats after ischemia under ACTH-like peptides Rat striatum and frontal cortex after tMCAO not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source samples analysed at 24 h after tMCAO Peptides normalized many ischemia‑related DEGs, with tissue-specific differences between frontal cortex and striatum
[S7] behavioral and histological preclinical study Transgenic APPswe/PS1dE9/Blg mice (Alzheimer's model) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Semax and a derivative improved performance on open field, novel object recognition, and Barnes maze tests and reduced amyloid inclusions in cortex and hippocampus
[S8] genome-wide transcriptional analysis in rat brain focal ischemia Rats with permanent middle cerebral artery occlusion (pMCAO) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source gene expression assessed at 3 h and 24 h after pMCAO Semax predominantly enhanced expression of immune-response genes and altered vascular-system related gene expression in ischemized cortex

Limitations and research gaps

  • Source-limited: the reviewed human evidence consists largely of small controlled imaging studies, older primary clinical reports, and observational comparisons rather than large, contemporary randomized clinical trials; many protocol details (exact doses, routes, timing) are not fully reported in the provided excerpts.
  • Preclinical-to-human translation: mechanistic and transcriptomic findings are robust in some animal models but cannot be assumed to generalize to humans without confirmatory clinical trials.
  • Some cited clinical reports are primary literature entries with limited accessible metadata in the reviewed excerpts; full trial methods and quality assessments are not available in the provided records.

Documentation checklist

  • Distinguish human clinical/imaging evidence from animal and cellular studies.
  • List only protocol details explicitly stated in reviewed excerpts; use 'not reported in the reviewed source' where absent.
  • Cite one or more reviewed source_ids for every factual claim about study design, outcomes, or mechanisms.
  • Flag evidence as source_limited when the corpus is incomplete, small, or heterogeneous.
  • Avoid treatment recommendations, dosing advice, or procedural instructions for personal use.
  • laboratory inventory labels and tracking sheets
  • ultra-low temperature freezer logbook
  • reagent storage boxes for refrigerated peptides
  • benchtop disinfectant wipes for equipment surfaces

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More Semax research

Sources and references

  1. [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
  2. [S2] Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV. Functional Connectomic Approach to Studying Selank and Semax Effects.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020. PMID: 32342318. DOI: 10.1134/S001249662001007X
  3. [S3] Liu R, Chen Y, Huang H, Li X, Lv J, Jiang L. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.. British journal of pharmacology. 2025. PMID: 40692165. DOI: 10.1111/bph.70122
  4. [S4] Tarasov VV, Kudryashov NV, Chubarev VN, Kalinina TS, Barreto GE, Ashraf GM. Pharmacological Aspects of Neuro-Immune Interactions.. Current pharmaceutical design. 2018. PMID: 28875850. DOI: 10.2174/1381612823666170829135115
  5. [S5] Filippenkov IB, Shpetko YY, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.. Biomedicines. 2024. PMID: 39767736. DOI: 10.3390/biomedicines12122830
  6. [S6] Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV. Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.. International journal of molecular sciences. 2025. PMID: 40650034. DOI: 10.3390/ijms26136256
  7. [S7] Radchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborska SA. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.. Acta naturae. 2025. PMID: 41479572. DOI: 10.32607/actanaturae.27808
  8. [S8] Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.. BMC genomics. 2014. PMID: 24661604. DOI: 10.1186/1471-2164-15-228
  9. [S9] Effects of Semax on the Default Mode Network of the Brain. primary literature
  10. [S10] [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. primary literature
  11. [S11] [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. primary literature
  12. [S12] [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. primary literature

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts